Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL
Nature Reviews Clinical Oncology, Published online: 15 November 2022; doi:10.1038/s41571-022-00711-4CAR T cell therapy has altered the natural history of relapsed and/or refractory diffuse large B cell lymphoma (DLBCL). However, the availability of multiple products has created provider uncertainty regarding treatment selection and the need to balance toxicity and efficacy. In a retrospective analysis, the authors suggest that axicabtagene ciloleucel might be superior to tisagenlecleucel. However, several questions remain unresolved. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 15, 2022 Category: Cancer & Oncology Authors: Richard T. Maziarz Jordan Gauthier Source Type: research
DREAMseq of therapy for BRAF-mutant melanoma
Nature Reviews Clinical Oncology, Published online: 09 November 2022; doi:10.1038/s41571-022-00708-zDREAMseq of therapy for BRAF-mutant melanoma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 9, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
From WCC 2022
Nature Reviews Clinical Oncology, Published online: 03 November 2022; doi:10.1038/s41571-022-00706-1From WCC 2022 (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 3, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Bemarituzumab enters the FIGHT
Nature Reviews Clinical Oncology, Published online: 02 November 2022; doi:10.1038/s41571-022-00705-2Bemarituzumab enters the FIGHT (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 2, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Targeting drugs to tumours using cell membrane-coated nanoparticles
Nature Reviews Clinical Oncology, Published online: 28 October 2022; doi:10.1038/s41571-022-00699-xOwing to several limitations, including elimination by the immune system and a lack of tumour specificity, systemically administered synthetic nanoparticles are used for a limited range of cancer indications. In this Review, the authors describe the potential of cellular nanoparticles (comprising a cell membrane coating around a synthetic core) to overcome these issues as well as their application in drug delivery, phototherapy and immunotherapy. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 28, 2022 Category: Cancer & Oncology Authors: Ronnie H. Fang Weiwei Gao Liangfang Zhang Source Type: research
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies
Nature Reviews Clinical Oncology, Published online: 28 October 2022; doi:10.1038/s41571-022-00696-0Neuroendocrine neoplasms (NENs), which can develop in almost any organ and range from indolent neuroendocrine tumours (NETs) to rapidly progressive and fatal neuroendocrine carcinomas (NECs), have historically been approached in a siloed manner according to their specific tissue of origin. However, NETs and NECs across different sites of origin often share genomic and phenotypic characteristics. In this Review, the authors discuss both the clinical and biological commonalities as well as key organ-specific differences of NENs...
Source: Nature Reviews Clinical Oncology - October 28, 2022 Category: Cancer & Oncology Authors: Kenta Kawasaki Natasha Rekhtman Álvaro Quintanal-Villalonga Charles M. Rudin Source Type: research
Towards clinical translation of FLASH radiotherapy
Nature Reviews Clinical Oncology, Published online: 27 October 2022; doi:10.1038/s41571-022-00697-zFLASH radiotherapy involves delivering ultra-high dose rates of radiation, which enables sustained tumour control with reduced toxicity to surrounding tissues. The authors of this Perspective describe the principles underlying FLASH radiotherapy, present the available evidence from preclinical studies testing this modality and discuss the challenges for its application in routine clinical practice. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 27, 2022 Category: Cancer & Oncology Authors: Marie-Catherine Vozenin Jean Bourhis Marco Durante Source Type: research
BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC
Nature Reviews Clinical Oncology, Published online: 21 October 2022; doi:10.1038/s41571-022-00698-yA high tumour mutational burden (≥10 mutations per megabase) is a companion biomarker in the histology-agnostic approval of pembrolizumab for treatment-refractory advanced-stage solid tumours, and continues to be an exploratory predictive biomarker for immune-checkpoint inhibitors in non-small-cell lung cancer. Herein, we discuss recent results from the first phase III trial evaluating blood-based tumour mutational burden in patients with treatment-naive advanced-stage non-small-cell lung cancer. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 21, 2022 Category: Cancer & Oncology Authors: So Yeon Kim Roy S. Herbst Source Type: research
Allogeneic CAR T cells show promise
Nature Reviews Clinical Oncology, Published online: 21 October 2022; doi:10.1038/s41571-022-00703-4Allogeneic CAR T cells show promise (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 21, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Systemic therapy for early-stage breast cancer: learning from the past to build the future
Nature Reviews Clinical Oncology, Published online: 17 October 2022; doi:10.1038/s41571-022-00687-1Systemic therapies for early-stage disease have been tested in clinical trials for decades. The authors of this Review provide an overview of the evolution of (neo)adjuvant trials from the pre-genomic to the post-genomic era, focusing on design, end points and biomarkers that, together, could enable the delivery of more personalized treatment. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 17, 2022 Category: Cancer & Oncology Authors: Elisa Agostinetto Joseph Gligorov Martine Piccart Source Type: research
Benefit with neoadjuvant pembrolizumab
Nature Reviews Clinical Oncology, Published online: 17 October 2022; doi:10.1038/s41571-022-00702-5Benefit with neoadjuvant pembrolizumab (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 17, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
GPRC5D-CAR T cells active in MM
Nature Reviews Clinical Oncology, Published online: 17 October 2022; doi:10.1038/s41571-022-00701-6GPRC5D-CAR T cells active in MM (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 17, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
Mitigating acute chemotherapy-associated adverse events in patients with cancer
Nature Reviews Clinical Oncology, Published online: 11 October 2022; doi:10.1038/s41571-022-00685-3Either alone or in combination, chemotherapy remains the mainstay treatment for most human malignancies. This treatment modality is associated with a high burden of chemotherapy-associated adverse events (CAAEs) that greatly affect patients because of their considerable morbidity, mortality and costs. Kuderer et al. discuss the pathophysiology, management and risk factors of the most common acute CAAEs with a major effect on survival, quality of life, function and/or continuation of optimal therapy. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 11, 2022 Category: Cancer & Oncology Authors: Nicole M. Kuderer Aakash Desai Maryam B. Lustberg Gary H. Lyman Source Type: research
Clinical implications of T cell exhaustion for cancer immunotherapy
Nature Reviews Clinical Oncology, Published online: 10 October 2022; doi:10.1038/s41571-022-00689-zT cells are key effectors of immunotherapies that have revolutionized the treatment of cancer; however, chronic exposure to tumour-associated antigens can result in progressive loss of T cell effector functions and self-renewal capacity, a state termed ‘T cell exhaustion’ that is believed to limit the efficacy of immunotherapy. This Review synthesizes the new immunobiological insights that present a more nuanced view beyond T cell exhaustion being entirely undesirable and indicate that this hypofunctional state might be a...
Source: Nature Reviews Clinical Oncology - October 10, 2022 Category: Cancer & Oncology Authors: Andrew Chow Karlo Perica Christopher A. Klebanoff Jedd D. Wolchok Source Type: research
The multiple roles of LDH in cancer
Nature Reviews Clinical Oncology, Published online: 07 October 2022; doi:10.1038/s41571-022-00686-2A high serum lactate dehydrogenase (LDH) level is generally associated with an inferior outcome in patients with most tumour types. LDH is also known to have immunosuppressive and/or tumour-promoting effects, suggesting a potentially broader role for this enzyme in clinical oncology. In this Review, the authors provide a holistic overview of the current role of LDH in both cancer biology and oncology, and highlight possible areas of future research interest, including the development of novel therapies targeting LDH. (Source:...
Source: Nature Reviews Clinical Oncology - October 7, 2022 Category: Cancer & Oncology Authors: Giuseppina Claps Sara Faouzi Virginie Quidville Feras Chehade Shensi Shen St éphan Vagner Caroline Robert Source Type: research
